We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Life Science Reit Plc | LSE:LABS | London | Ordinary Share | GB00BP5X4Q29 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.10 | 0.30% | 33.10 | 764,517 | 15:35:35 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 33.10 | 33.40 | 33.40 | 32.80 | 33.40 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Real Estate Investment Trust | 19.94M | -21.71M | -0.0620 | -5.34 | 115.5M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:19 | UT | 43,072 | 33.10 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 20/6/2024 | 15:55 | ALNC |  Best and worst performing London-listed funds in May - QuotedData |
| 28/5/2024 | 07:00 | UK RNS | Life Science REIT PLC Appointment of new team members |
| 23/5/2024 | 17:00 | UK RNS | Life Science REIT PLC Result of AGM |
| 08/5/2024 | 17:13 | UK RNS | Life Science REIT PLC Holding(s) in Company |
| 07/5/2024 | 07:00 | UK RNS | Life Science REIT PLC Purchase of Ordinary Shares by Investment Adviser |
| 01/5/2024 | 10:24 | UK RNS | Life Science REIT PLC Holding(s) in Company |
| 30/4/2024 | 13:24 | UK RNS | Life Science REIT PLC Holding(s) in Company |
| 26/4/2024 | 13:47 | UK RNS | Life Science REIT PLC Holding(s) in Company |
| 25/4/2024 | 16:23 | UK RNS | Life Science REIT PLC Holding(s) in Company |
| 25/4/2024 | 16:04 | UK RNS | Life Science REIT PLC Notice of AGM |
Life Science Reit (LABS) Share Charts1 Year Life Science Reit Chart |
|
1 Month Life Science Reit Chart |
Intraday Life Science Reit Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 24/7/2024 | 07:58 | LIFE SCIENCE REIT | 297 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 15:35:19 | 33.10 | 43,072 | 14,256.83 | UT |
| 2024-07-26 15:19:29 | 33.40 | 274,100 | 91,549.40 | O |
| 2024-07-26 15:19:17 | 33.39 | 274,100 | 91,521.99 | O |
| 2024-07-26 14:35:35 | 33.10 | 300 | 99.30 | AT |
| 2024-07-26 14:31:19 | 33.30 | 2,900 | 965.70 | AT |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Life Science Reit Daily Update Life Science Reit Plc is listed in the Real Estate Investment Trust sector of the London Stock Exchange with ticker LABS. The last closing price for Life Science Reit was 33p.Life Science Reit currently has 350,000,000 shares in issue. The market capitalisation of Life Science Reit is £115,850,000. Life Science Reit has a price to earnings ratio (PE ratio) of -5.34. This morning LABS shares opened at 33.40p |
Posted at 24/7/2024 07:58 by ghhghh The short term risk is Oxford Technology Park. LABs need to start letting out the speculative new space they are building. Accepted we’ve had an Election and everyone appears to be on holiday at the moment but I will begin to worry if nothing announced by mid August.All LABs have told me is that very busy…. However mid term I think LABs is a stunning buy. OTP is immediately north of Begbroke’s existing Science Park owned by the University. OTP is better located, fronting Oxford Airport. The University are currently seeking planning for: Begbroke Science Park is in the middle of all the fields. OTP is a field away from the proposed Innovation site boundary. Google search…. This is encouraging for two reasons. It illustrates significant future demand and that OTP is well located. |
Posted at 20/6/2024 16:59 by wshak There is a clear and obvious thing to do.Sell the prime asset, Herbrand St, use a bit to lower debt and the rest to tender for shares in a reverse Dutch auction.It is an obvious move, given the share price.If they don't do it, someone will take them out. |
Posted at 19/6/2024 15:20 by wshak It's not for me to persuade anyone to buy, but LABS strikes me as being very similar to Quintain Estates (QED) back in the day during the financial crisis.Traded at a fraction of NAV which no-one believed in. Management was overly ambitious and had paid too much for assets, and a large part of them were at development stage. Bought at the right price, the shares were a great buy - and they didn't even pay a dividend. I still remember picking up a load of shares in Quintain Estates when everyone wanted out - I think the market cap was £200m at the time. A few years later, it was bought out for £700m by Lone Star. A few years after that, Guy Hands was in the market to buy it for £2.5bn. I didn't make nearly as much out of it as I should have but, even so ... I agree with Paul that the main risk is not that the NAV of the properties is fake but in making sure they get tenants in once build-out is complete. There are "easier" property REITs to buy into out there but the discount available here justifies a place in the portfolio, alongside the others. Maybe the shares go to 25p if selling continues - who knows? I still think that the shares I've bought will all be sold at a profit eventually, nevertheless. In the meantime, the company is subscale and an obvious takeover target for a cheap underbidder, given where the shares are trading. |
Posted at 18/6/2024 13:38 by ghhghh LogThe more I look at LABS the more I think that they are just a sub-scale office REIT trying to grift by saying they have some sort of edge selling lab space. Can you be more specific? They have 4 assets. OTP the largest at over £150m completed. New build so unless they've really screwed up it's a Science Park!! Can they let it all....? Herbrand St valued at £70m. It's a decent asset and should still have value as HQ offices. Rolling Stock Yard at £83m - very well located by Kings Cross and already part labs. Evidently in one of the 'greatest knowledge clusters in the world'! Cambourne Park at £81.6m - good road links just outside Cambridge plus parking so easy access. I'll sit on the fence re Lab conversion but it looks a reasonably decent asset. |
Posted at 17/6/2024 10:37 by sebass Can anyone guess a timeline on page 29 to achieving 26.2m ERV? My main reservation is how fast an incoming labour governemnt would be able to energise planning for labs leading to oversupply of labs down the road |
Posted at 13/6/2024 16:11 by ghhghh CatabritThanks for your post which I've copied to LABs for their comments. With the exception of Rolling Stock Yard and Herbrand Street, these are all very secondary assets. OTP (next to Oxford Airport) and Cambourne looks an okay locations to me. Cambourne Park is immediately adjacent to a junction on the dual carriageway A428 connecting to the M11. Cambridge has a tonne of spec supply available and in far superior locations than Cambourne I'll be interested to see LAB's take on this since they are forever plugging the attractive supply demand metrics. Can you please provide details of this 'tonne of spec supply in far superior locations'. On my very crude napkin math I am not getting much above £220m of gross asset value which is basically the market cap + debt. And I don't think I was that stingy either. Maybe I was too mean on the London assets but even being generous / fair they barely add more than 20-30m extra to that total (10-15% upside). Difficult to comment on this without knowing the breakdown. I was impressed when I meet the LABs team and the CV's of the BoD and management team team appear highly credible. Hence I'd be surprised if the realisable NAV is effectively half of their claimed NAV. |
Posted at 23/5/2024 09:19 by jpatara3 It begs the question "what is LABS management doing?", we have a life sciences sector worth over £90billion, employing over 300,000. This sector is struggling to find space and the rents are soaring. Even with more competition the sector will still require more quality labs. |
Posted at 20/5/2024 08:41 by cwa1 Someone mentioned LABS to me the other day, so I thought I must have a look. I've had barely a 5 minute look so far, so barely even scratched the surface...The share price chart looks brilliant, just the way I like it(unless, of course, they are genuinely awful/about to go bust). A lot of the portfolio is in offices. As Graham Taylor once said: Do I NOT like that. I suppose there's an argument that it's "all in the price" already however? Recent dividend cut...errr, sorry, "rebasing". Clearly not good news from an investor point of view but sensible from a business standpoint I feel. However there are loads of chunkier yields out there that remunerate you handsomely whilst you wait for the company to re-rate. So not perfect. There looks to be a willing and commited seller out there. That cuts two ways of course but I'd rather be buying when there selling was coming to an end/drying up. Having said that, it's worth a deeper look as there's a bit to do to understand it. Anyone care to add their tuppence worth? Or even just ring a bell when it's at the bottom? ;-) |
Posted at 27/3/2024 10:00 by williamcooper104 On 1 - LABS are right; there is currently still significant unmet demand - plus developing in Oxford and Cambridge is very difficult - no electricity in Oxford (labs use a lot) and no water in Cambridge. Within next 5-7 years there's a lot more supply coming into London - but that's not a problem now - and if I was buying into LABS now it would be on the basis of a wind up2 - market has more of a point here - it's not that you can't convert to labs but that those labs will always be inferior to purpose built, plus in urban areas you might have to internally store your plant losing a lot of lettable floor area - but that's more of a longer term problem- and as said these are not RGLO offices |
Posted at 27/3/2024 09:25 by ghhghh My take is that LABS is selling off because1. Market doesn't believe that there is enough mid term demand for Lab space but LABS claim that interest/demand (stacked up by concerns re economy)is significantly greater than current supply and this imbalance is increasing thanks to reduced new build) 2. Market is valuing LABS on the basis of it's high % of offices, tarnishing it with the same obsolete/stranded assets discounts as RGL/CLS etc. But as far as I'm aware, all LABS offices have been acquired on the basis that they will be converted. Hence no concerns here (other than future funding) and the greater the write downs, the greater the valuation uplift on refurb, build cost inflation aside. LAB's portfolio is already 100% A-C ESG when you exclude the one listed building. And as far as I'm aware, they have no other significant funding commitments other than Oxford which is covered in Results? I'll double check with them. I should get the Jefferies Note within a couple of days, this should add to the bear case! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
